EUVIMEDEUVIMED entdecken
Crossref

Temperature management after cardiac arrest: what is next after the TTM-2 and BOX trials?

Fabio Silvio Taccone, Filippo Annoni

European Heart Journal: Acute Cardiovascular Care · 2023

DOI: 10.1093/ehjacc/zuad088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2023. Verfasst von Fabio Silvio Taccone und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Route de Lennik, 808, 1070 Brussels, Bel…. Hauptthemen laut MEDLINE: Heart Arrest, Hypothermia, Induced, Out-of-Hospital Cardiac Arrest, Cardiopulmonary Resuscitation. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Out-of-hospital cardiac arrest (OHCA) is a life-threatening condition associated with high morbidity and mortality rates. Recent publications of the multi-centre BOX and TTM-2 trials have provided valuable insights into temperature management after OHCA. The TTM-2 study compared hypothermia (target temperature of 33°C) with strict normothermia (target temperature below 37.7°C).1 The main results showed no significant difference in survival rates or neurological outcomes between the two temperature groups, even among pre-specified subgroups. Interestingly, the hypothermia group had an increased risk of severe arrhythmias, suggesting that normothermic targets may be preferable in this context. The BOX trial examined the effects of active device-based fever prevention for either 36 or 72 h after OHCA.2 At 90 days, there was no significant difference in all-cause mortality or severe cerebral disability or coma between the two groups. This finding was consistent across different subgroups, including older patients and those with coexisting conditions. These trial results have significant implications for clinical practice. Following the TTM-2 trial, international guidelines now recommend actively preventing fever (defined as a temperature above 37.7°C) in comatose cardiac arrest patients for at least 72 h.3 The possibility of shortening the duration of fever prevention to 36 h is still under discussion, but some centres have already implemented this approach. Shortening the duration of fever prevention could potentially reduce the use of sedatives and hasten patient awakening. The strengths of these studies lie in their large cohorts of randomized patients, robust methodology with adequate sample sizes, allocation concealment, blinding of assessors, and implementation of protocolized care to minimize variability in patient management. However, contextualizing these findings with existing evidence and ongoing clinical trials on temperature management after cardiac arrest is important. Both the TTM-2 and BOX trials focused on OHCA patients, and their results may not directly apply to other populations, such as in-hospital cardiac arrest (IHCA) patients. In the HYPERION study, which included a subgroup of 159 IHCA patients, hypothermia at 33°C was associated with a higher proportion of patients alive with good neurological outcomes at day 90 as compared to normothermia (16.4% vs. 5.8%; P = 0.03), while mortality was not significantly different between the two groups.4 However, another randomized trial including 249 IHCA patients found similar proportions of patients with favourable neurological outcomes between the hypothermia and normothermia groups.5 These discrepant results may be influenced by differences in temperature control strategies, management protocols, or inclusion criteria, highlighting the need for a large randomized trial specifically investigating the role of hypothermia in IHCA. The efficacy of targeted temperature management may differ in patients with non-shockable rhythms, such as pulseless electrical activity or asystole, compared with those with shockable rhythms, which were predominantly represented in the TTM-2 and BOX trials. Additionally, the majority of patients included in these trials had witnessed arrest and received bystander cardiopulmonary resuscitation (CPR), resulting in a short time from arrest to initial resuscitation attempts.1,2 The BOX trial reported a high proportion of patients (more than 65%) surviving with good neurological outcomes, suggesting a possible selection bias towards patients with the highest probability of neurological recovery (i.e. shockable rhythm, cardiac cause, immediate resuscitation).2 However, a significant proportion of cardiac arrest patients present with non-cardiac causes of arrest, lower rates of bystander CPR, and longer resuscitation times, which are associated with more severe brain injury and lower chances of recovery.6 Recent studies have demonstrated that the presence of bystander CPR may reduce the potential benefit from hypothermia in OHCA patients.7,8 Furthermore, the use of hypothermia in cardiac arrest patients requiring extracorporeal membrane oxygenation may have a more favourable prognosis, although the available evidence is still uncertain.9 Therefore, the results of the TTM-2 and BOX trials may not be directly applicable to all cardiac arrest patients (Figure 1), and further research is necessary to explore the effectiveness of hypothermia in different patient populations. Illustration depicting the applicability of the findings coming from the most relevant randomized trials dealing with targeted temperature management after cardiac arrest, according to cardiac arrest location, IHCA, in-hospital; OHCA, out-of-hospital. Due to the unresolved research questions, several ongoing or upcoming studies are addressing temperature management in cardiac arrest patients. The ICECAP study (NCT04217551) is a multi-centre, randomized, adaptive allocation clinical trial aiming to determine the optimal duration of induced hypothermia for neuroprotection in 1800 comatose survivors of cardiac arrest. This study hypothesizes that longer cooling durations may enhance neurological recovery rates. Although this hypothesis may seem contradictory to the results of the BOX study, a previous underpowered randomized trial demonstrated a non-significant 6% reduction in mortality when unconscious OHCA survivors were subjected to targeted temperature at 33°C for 48 h compared with 33°C for 24 h.10 The IH-TTM study is set to commence in France, Belgium, and other European countries. It aims to evaluate the effects of hypothermia at 33°C for 24 h vs. normothermia (below 37.7°C) in approximately 800 IHCA patients. This study will contribute to understanding the impact of hypothermia in this setting. The PRINCESS-II study will be conducted across various European countries and USA. It seeks to assess whether initiating early selective brain cooling during CPR or immediately after the return of spontaneous circulation improves the proportion of OHCA patients with an initial shockable rhythm who achieve a favourable neurological outcome. The study design is based on the individual patient meta-analysis results from Phase-II and Phase-III studies that showed the effects of this approach in OHCA patients with ongoing CPR.11 Furthermore, the STEPCARE trial (NCT05564754) has been designed to investigate the effects of three interventions in comatose OHCA patients (i.e. sedation, temperature, and mean arterial pressure targets). In particular, patients will be randomized to fever management with or without a feedback-controlled device. These ongoing and forthcoming randomized trials will provide additional evidence regarding the role of hypothermia and temperature control in cardiac arrest patients across different clinical settings. By addressing key questions, they will further inform clinical practice and optimize patient care in the management of these patients. While the results of these two trials1,2 offer valuable insights, future research should focus on individualizing the selection of patients eligible for inclusion in randomized trials. Cardiac arrest is a diverse condition characterized by varying degrees of ischaemic and reperfusion injury, leading to a wide range of clinical presentations and outcomes. The severity of organ damage and potential for recovery can significantly differ among individuals experiencing cardiac arrest. Consequently, patient care must be tailored to their unique circumstances, rather than relying on a single intervention deemed universally ‘effective’ or ‘ineffective’ for all patients. Instead of relying on imprecise estimates, such as patient characteristics, comorbidities, initial rhythm, or resuscitation duration to gauge post-anoxic brain injury, it is advisable to implement neuromonitoring to quantify the extent of the initial injury. Patients with mild anoxic injury, who demonstrate early motor response localizing pain or exhibit an early electroencephalographic (EEG) tracing indicating a continuous and reactive background, may not be suitable candidates for studies evaluating temperature management.12,13 These patients have a high likelihood of rapid recovery, regardless of specific interventions, and thus may not benefit from neuroprotective strategies. Conversely, patients who exhibit an absence of pupillary light reflex upon admission, as assessed by automated pupillometry, have less than a 5% chance of neurological recovery.14 Due to the severity of their initial injury, which renders interventions ineffective, these patients should not be subjected to randomization. Although incorporating neuromonitoring may be challenging in this context, EEG has already been utilized in newborns with peri-partum asphyxia to identify candidates for hypothermia treatment.15 Additional neuromonitoring tools, such as cerebral ultrasound and/or biomarkers, should be further investigated for their feasibility and reliability in the early assessment of brain injury in cardiac arrest patients to identify those who might be enrolled in future trials on temperature management. The recent release of the BOX and TTM-2 trials has yielded significant knowledge regarding the optimal temperature management for patients experiencing OHCA. Although these trials have addressed certain aspects, there remain several areas that warrant further investigation. Precisely defining the appropriate patient population, target temperature, and duration of temperature management is crucial in the post-cardiac arrest care continuum. Therefore, future studies should focus on evaluating the effectiveness of interventions within specific or selected patient subgroups, aiming to provide personalized and evidence-based care for the implementation of hypothermia in this context. The inclusion of neuro-monitoring can play a pivotal role in the selection of the most suitable patients for future trials and in assessing the response to interventions. None declared. No new data were generated or analysed in support of this research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart ArrestHypothermia, InducedOut-of-Hospital Cardiac ArrestCardiopulmonary ResuscitationHumansTemperatureBody Temperature

Autor:innen und Institutionen

  • Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Route de Lennik, 808, 1070 Brussels, Belgium.

Zitieren

APA

Taccone, F. S., & Annoni, F. (2023). Temperature management after cardiac arrest: what is next after the TTM-2 and BOX trials?. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuad088

Vancouver

Taccone FS, Annoni F. Temperature management after cardiac arrest: what is next after the TTM-2 and BOX trials?. European Heart Journal: Acute Cardiovascular Care. 2023. doi:10.1093/ehjacc/zuad088

BibTeX
@article{Taccone2023,
  author = {Taccone, Fabio Silvio and Annoni, Filippo},
  title = {Temperature management after cardiac arrest: what is next after the TTM-2 and BOX trials?},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2023},
  doi = {10.1093/ehjacc/zuad088}
}
Kostenlos starten →